CD80
Overview
CD80 (also known as B7-1) is a co-stimulatory ligand expressed on antigen-presenting cells that binds CD28 on T cells to provide the co-stimulatory second signal for T-cell activation, and also binds CTLA-4 with higher affinity to deliver an inhibitory signal. In the tumor microenvironment, CD80 expression on tumor cells or infiltrating immune cells can modulate T-cell responses. Under immune checkpoint blockade, CD80 expression is induced as part of the pharmacological on-therapy immune activation program.
Alterations observed in the corpus
- CD80 was upregulated on-therapy in melanoma patients receiving nivolumab (anti-PD-1), as part of a 475-gene pharmacologic on-therapy response set (q < 0.20) regardless of clinical response category. CD80 was specifically named among immune checkpoint genes upregulated on-therapy: PDCD1, CD274, CTLA4, CD80, ICOS, LAG3, and TNFRSF9. PMID:29033130
Cancer types (linked)
- SKCM: CD80 was among the immune checkpoint and co-stimulatory genes consistently upregulated on-therapy under nivolumab across ipilimumab-naive and ipilimumab-progressed melanoma patients, independent of clinical response. CD80 upregulation was also enriched in the genomic-contraction-phenotype DEG set. PMID:29033130
Co-occurrence and mutual exclusivity
Therapeutic relevance
- CD80 induction on-therapy under nivolumab reflects the broader immune activation pharmacodynamic response. The dual role of CD80 as a CD28 agonist and CTLA-4 ligand makes it a mechanistic link between anti-PD-1 and anti-CTLA-4 combination strategies. PMID:29033130
Open questions
- Whether on-therapy CD80 levels differentiate patients who will experience durable responses vs early progression was not specifically reported. PMID:29033130
Sources
This page was processed by crosslinker on 2026-05-15.